Sugar Land, TX – Acute Myeloid Leukemia (AML) remains one of the most challenging hematological malignancies to treat, with relapse and refractory cases continuing to pose significant hurdles. Traditional therapies have improved survival rates, but new strategies are essential for more durable responses. Among the emerging therapeutic options, Natural Killer...
Latest News
HAMPTON, N.J., – Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 1 study of CDX-0159 for the treatment of prurigo nodularis (PN). CDX-0159 is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits...
FLORHAM PARK – Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the European Medicines Agency has adopted a positive opinion for CLR 131 orphan designation for the treatment of Waldenstrom’s Macroglobulinemia...
Vienna, Austria – Nightshade plants produce a diverse array of compounds with therapeutic potential. Researchers at CeMM have now identified an artificial variant inspired by the Withanolides group that acts highly specifically against leukemia cells. Using state-of-the-art chemical and genetic high-throughput analyses, the team led by Georg Winter not only...
ST. LOUIS, Dec. 15, 2020 — Centene Corporation (NYSE: CNC) today announced it has signed a definitive agreement to acquire PANTHERx, one of the largest and fastest-growing specialty pharmacies in the United States specializing in orphan drugs and rare diseases. The transaction is subject to regulatory approvals and is expected to close by the end of 2020....
ORANGE, Calif. — Today, the Center for Inherited Blood Disorders (CIBD) announced the successful administration of the first gene therapy infusion in the country to treat hemophilia A outside of the clinical trial setting. The landmark infusion, administered by CIBD’s skilled medical team, is a testament to the center’s commitment...
HOPEWELL, N.J. – Capital Health’s Center for Neuro-Oncology, part of Capital Institute for Neurosciences and the Capital Health Cancer Center, continues to demonstrate nationally the program’s leadership and commitment to clinical excellence. Over the last month, the center’s neurosurgical director, Navid Redjal, MD, FAANS, led publication of guidelines for the treatment...
TAYLOR — Seeking a larger house to accommodate a growing family, nine years ago Chris and Barb Savoie moved from Southgate to Taylor a month after their youngest daughter, Nikki, was born. The house is about 1 1/2 miles from Penrickton Center for Blind Children. At the time, the couple...
CAMBRIDGE, Mass. and ROSTOCK and BERLIN, Germany and SOUTH SAN FRANCISCO, Cal. – Centogene N.V. (Nasdaq: CNTG), a commercial-stage Company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, and Twist Bioscience Corporation (Nasdaq: TWST), a Company enabling customers to succeed through its offering of high-quality synthetic...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today research revealing six novel gene-disease associations for a wide range of genetic disorders...